Premium
Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia
Author(s) -
Laundy G.J.,
Bradley B.A.,
Rees B.M.,
Younie M.,
Hows J.M.
Publication year - 2004
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2004.03387.x
Subject(s) - epitope , antibody , aplastic anemia , human leukocyte antigen , immunology , serology , medicine , isoantibodies , incidence (geometry) , antigen , bone marrow , physics , optics
BACKGROUND: This study aimed to establish the prevalence and characteristics of anti‐HLA in antibody acquired aplastic anemia patients following cessation of antithymocyte globulin therapy and to characterize antibody in terms of epitope specificity. STUDY DESIGN AND METHODS: One hundred and fifty multitransfused, untransplanted patients from eight European centers were investigated by serologic methods. RESULTS: Sixty‐two percent were antibody positive. Eighteen HLA‐Class‐I‐specific antibodies (15 IgG, 3 IgM) were identified in 13 patients; 13 antibodies were specific for HLA‐A epitopes and 5 for HLA‐B. Epitope analysis identified significant correlation between serum reactivity and amino acid substitutions associated with HLA‐Class‐I epitopes. An excess of antibodies to HLA‐A1‐associated cross‐reactive groups was identified. There was no significant difference in antibody frequency in patients taking cyclosporine compared to those who were not. CONCLUSION: Data suggested a contribution from B cell memory of alloantigens introduced during pregnancy. In some cases, antibody production continued many years after the last transfusion, and although the target varied between individual patients, the antibody to HLA was focused on a few specific Class I epitopes, the majority of which mapped to the HLA‐A molecule.